189281-66-1

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2,6-DICHLORO-5-FLUORONICOTINATE is used as a building block for the synthesis of various bioactive molecules, contributing to the development of new pharmaceutical compounds.
Used in Agrochemical Development:
METHYL 2,6-DICHLORO-5-FLUORONICOTINATE is used as a component in the development of agrochemicals, leveraging its potent insecticidal activities for pest control in agriculture.
Used in Disease Treatment Research:
METHYL 2,6-DICHLORO-5-FLUORONICOTINATE is used as a subject of study for its potential application in the treatment of various diseases, exploring its therapeutic properties.
Used as an Intermediate in Pharmaceutical Production:
METHYL 2,6-DICHLORO-5-FLUORONICOTINATE is used as an intermediate in the production process of various pharmaceutical compounds, facilitating the synthesis of active ingredients.

InChI:InChI=1/C7H4Cl2FNO2/c1-13-7(12)3-2-4(10)6(9)11-5(3)8/h2H,1H3

Upstream product

• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 67-56-1 methanol 
• 189281-08-1 ethyl 5-amino-1-(6-amino-3,5-difluoropyridin-2-yl)-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 4732-69-8 Chloro-oxo-acetic acid 

Downstream Products

• 1226550-86-2 methyl 2-chloro-6-(dimethylamino)-5-fluoronicotinate 
• 1253383-91-3 5-fluoro-6-methylnicotinic acid methyl ester 
• 932705-78-7 5-fluoro-6-methylnicotinic acid 
• 1253383-92-4 benzyl (5-fluoro-6-methylpyridin-3-yl)carbamate 
• 1211542-12-9 5-fluoro-6-methylpyridin-3-amine 
• 884494-73-9 5-fluoro-6-methoxynicotinaldehyde 

Relevant academic research and scientific papers

Nitrogen-containing polycyclic compound as well as preparation method and application thereof

The invention discloses a nitrogen-containing polycyclic compound as well as a preparation method and application thereof, and particularly relates to a nitrogen-containing polycyclic compound as shown in a general formula I, or pharmaceutically acceptable salts thereof, or enantiomers, diastereoisomers, tautomers, torsional isomers, solvates, polymorphic substances or prodrugs thereof, as well asa preparation method and pharmaceutical application thereof. The definition of each group is as shown in the specification.

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

Fused cyanopyridine compound and preparation method and application thereof

The invention discloses a fused cyanopyridine compound shown as a general formula I-1 or I-2, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorphic substance or a prodrug thereof, and a preparation method and a pharmaceutical application of the fused cyanopyridine compound, wherein the definition of each group is shown in the specification.

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

NOVEL COMPOUNDS

The preseent invention relates to novel retinoid-related orphan receptor gamma(RORγ)modulators and their use in the treatment ofdiseases mediated by RORγ.

NOVEL COMPOUNDS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME

The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.